About Caplin Point Laboratories Limited

The pharmaceutical company Caplin Point Laboratories Limited operates from Chennai as its headquarters since 1990 while using a 100% export-oriented model to serve Latin America and Africa and expanding its reach into USA and Canada and Australia markets.  The company produces a complete range of pharmaceutical product line which includes tablets and capsules and injectables (liquid and lyophilised and pre-filled syringes) and ophthalmics and liquid orals and softgels and ointments and creams and gels and powders for injection and suppositories and ovules and derma-cosmetics and surgicals and disposables and premix bag formulations and inhalers and sprays and IV infusions.  The company operates six state-of-the-art manufacturing facilities between Tamil Nadu and Andhra Pradesh while maintaining multiple R&D centers which include clinical research and API development capabilities.

The company expanded its operations from 10 countries in 2 regions to 55 countries across 6 regions through its distribution network ownership strategy which targets Bottom of the Pyramid consumers in its core markets. The company operates through 5 subsidiaries and 7 step-down subsidiaries and maintains an associate entity according to its March 31, 2025 financial reports. The company achieved three major milestones by entering regulated markets through sterile injectables and establishing its own-label front-end in the US and receiving multiple Forbes Asia “200 Best Under a Billion” list recognitions including the 2024 edition.

Caplin Point Laboratories Limited’s Business Segments

• The company generates 77% of its revenue from Latin America while the US and other regulated markets bring in 18% and Africa contributes 5% to the total revenue during FY2024-25.
• The company generates all its revenue from exports because it does not market its products in India and distributes to 55 countries worldwide.

Caplin Point Laboratories Limited Key Management

• C. C. Paarthipan serves as Chairman (Non-Executive Promoter) of the company.
• Dr. Sridhar Ganesan serves as the Managing Director of the organization.
• D. Muralidharan holds the position of Chief Financial Officer at the company.
• P. Vivek Siddarth serves as the Chief Operating Officer of the organization.
• The company has Venkatram G as its General Counsel and Company Secretary.

Latest Updates on Caplin Point Laboratories Limited

• The US front-end operations of the company achieved $3.2 Million in revenue during the first eight months of operation while launching 24 products and establishing partnerships with seven major wholesalers and twenty-four hospital-system buyers and reaching 5,610 end users including hospitals and pharmacies and clinics.
• The company achieved eight new ANDA approvals through Caplin Steriles during FY25 while its total ANDA approvals reached 38 and it launched three new products including RTU bags and ophthalmic emulsions and injectable emulsions and plans seven pre-filled syringe filings for FY26.
• The company obtained market access through regulatory approvals in Canada and Mexico and UAE and Saudi Arabia and South Africa and Brazil and expects revenue from Canada (8) and Mexico (4) and Australia (3) during FY26–27. 
• The Mexican market has received more than 35 product filings which resulted in 17 product approvals while the company plans to submit 80+ additional products for approval through internal and outsourced manufacturing within the next 12 months.
• Amaris Clinical (CRO) received clearance for a virtual inspection from ANVISA-Brazil while the company finished 15 in-house BE/BA studies for LatAm filings and API R&D reached 90+ molecules and dual-chamber pre-filled syringes will enter multiple markets.
• The company received two major recognitions in 2024 when Forbes Asia included it in their “200 Best Under a Billion” list and Hurun India also recognized the company.